Uploads:
- Deliverable 4.10 2nd Report on stakeholder consultation and mapping of needs Info
- Additional Deliverable 5.5 Generating indicators incorporating HBM-GV – first visualisation examples Info
- Additional Deliverable 13.7 Draft guidance and recommendations for risk assessors and policymakers on the use of mechanistic toxicology data and AOPs Info
- Deliverable 15.5 Case study reports on mixture health effects Info
- Deliverable 6.4 Revised report on national needs, objectives of a long-term HBM4EU inventory of funding mechanisms and recommendations for a sustainable HBM initiative in Europe and its organisation Info
- Deliverable 7.9 Overall report on WP7 documents for survey design, Study protocols, SOPs and Guidelines, and questionnaires Info
- Deliverable 16.4 Emerging exposure markers database - Reference Mass Spectral Libraries for Suspect Screening of Chemicals of Emerging Concern Info
- Deliverable 5.14 Derivation of Bisphenol A HBM Guidance Values (HBM-GVs) for the general population and occupationaly exposed adults Info
- Additional Deliverable 12.9 Report on biochemical/metabolic interactions among mixture components based on computational modelling Info
- Additional Deliverable 8.3 Implementation of effect biomarkers and implementation of 2nd set priority chemicals in the aligned studies Info
- Deliverable 5.8 Human Biomonitoring in risk assessment: 3rd set of examples on the use of HBM in risk assessments of HBM4EU priority chemicals Info
- Deliverable 5.6 Derivation of Human Biomonitoring Guidance Values (HBM-GVs) for selected phthalates Info
- Deliverable 5.15 Derivation of HBM guidance values (HBM-GVs) for Cadmium: for the general population and for workers Info
- Deliverable 2.13 2021 Strategy for the communication and dissemination of HBM4EU results Info
- Deliverable 14.7 Guidelines for the validation of biomarkers of effect: implementing quality assurance, trueness, precision, and accuracy as well as the availability of quality control measures by qualified laboratories Info
- Additional Deliverable 4.2 Report of the citizens’ focus groups Info
- Additional Deliverable 5.4 Reporting for first and second set of substances Info
- Deliverable 2.15 2021 Programme of training activities, materials and capacity building mechanisms Info
- Deliverable 10.10 Statistical analysis plan for the co-funded studies of WP8 Info
- Deliverable 7.8 Report on ongoing activities and existing data and data gaps Info
- Deliverable 10.7 Revised Data Management Plan (DMP) Info
- Deliverable 4.9 Scoping documents for 2021 for the first and second second round HBM4EU priority substances Info
- Additional Deliverable 8.5 Summary Report of Task 8.2 Activities Info
- Deliverable 2.14 Third review of training methods Info
- Deliverable 12.7 Biological half-life and internal dosimetry of the 2nd set of priority compounds Info
- Additional Deliverable 5.9 Timelines of opportunity: How HBM4EU can support chemicals management policy needs Info
- Additional Deliverable 9.6 Partners performing chemical analyses of substances on the 1st priority list in the aligned studies Info
- Additional Deliverable 6.3 Legacy of HBM4EU for a new partnership Info
- Additional Deliverable 6.2 Results of the interaction and surveys with the Environment Protection Agency network and the National Reference Centre on Environment & Health Info
- Deliverable 13.4 Report on AOPs of priority substances Info
- Deliverable 8.8 Progress report on strategies adopted to align HBM studies across Europe and preliminary results Info
- Additional Deliverable 12.10 Report on the parameterization of the 2nd set of priority compounds Info
- Additional Deliverable 8.4 Detailed research plan for the occupational diisocyanate and E-waste study Info
- Deliverable 10.6 Second annual list of exposure distributions and/or European Reference Values Info
- Deliverable 14.5 Selection criteria and inventory of effect biomarkers for the 2nd set of substances Info
- Additional Deliverable 4.3 Improvement of the strategy for the prioritisation of substances under HBM4EU Info
- Deliverable 2.12 2020 Programme of training activities, materials and capacity building mechanisms Info
- Deliverable 15.4 Report on approaches to identify mixture health effects Info
- Deliverable 8.6 Second report on biobank activities Info
- Deliverable 15.1 Information needs from policy makers translated in terms of functionality of HBM mixture information Info
- Deliverable 2.10 2020 Strategy for the communication and dissemination of HBM4EU results Info
- Deliverable 2.11 2nd Review of Training Methods Info
- Additional Deliverable 5.3 Case-study report on HBM-indicators Info
- Additional Deliverable 9.3 Report on activities in the analytical phase Info
- Deliverable 8.7 Second report on targeted new fieldwork and results Info
- Additional Deliverable 12.8 Review of available models for the 2nd set of prioritised substances Info
- Additional Deliverable 12.7 Report on optimised sampling schemes for rapidly metabolised and persistent/biocumulative substances Info
- Additional Deliverable 15.7 Joint survey of pesticides: details of approach and contributions Info
- Additional Deliverable 5.2 Reporting for first set of substances Info
- Deliverable 4.7 Scoping documents for 2020 - 2nd set of priority substances - Update of policy questions and related HBM4EU activities Info
- Deliverable 9.7 First report on analytical results and new methods development Info
- Deliverable 2.8 2019 Programme of training activities, materials and capacity building mechanisms Info
- Additional Deliverable 16.5 Updated prioritised list of known emerging chemicals. Updated list of known chemicals (parent compounds or metabolites) to be considered as exposure markers of emerging concern Info
- Additional deliverable 7.1 Upgrade of the strategy for human sample exchange, including SOPs Info
- Additional Deliverable 12.5 Delivery of exposure estimates for the 1st set of prioritised substances based on HBM data Info
- Additional Deliverable 12.3 Exposure model testing results Info
- Deliverable 12.4 Report on estimation of relevant tissue and biological fluid doses of 1st set of priority compounds in the EU population using refined PBTK modelling Info
- Deliverable 6.5 Sustainability of HBM4EU in the future and related operational architecture concept: first report Info
- Deliverable 6.2 Revised set of key indicators Info
- Deliverable 2.9 Summary report on helpdesk activities Info
- Additional Deliverable 14.5 Report on the 2nd Granada Workshop: Implementing Effect Biomarkers Info
- Additional Deliverable 11.3 Selection of feasibility studies for linking HBM and health studies, and linking to administrative data sources Info
- Deliverable 10.5 Statistical Analysis Plan Info
- Deliverable 13.5 Identified gaps for the establishment of AOPs and required studies Info
- Deliverable 5.5 Human biomonitoring in risk assessment: 2nd set of examples on the use of HBM in risk assessments of HBM4EU priority chemicals Info
- Deliverable 2.6 First review of training methods Info
- Additional Deliverable AD12.6 “Optimised algorithms for reverse dosimetry“ Info
- Deliverable 11.3 - Report on opportunities and obstacles of combining HBM and health studies, availability of health studies with biological samples, availability of administrative registers, and guidelines for combining HBM and health studies for the 2nd prioritisation round of substances Info
- Deliverable 9.6 - Databases of candidate laboratories for the 2nd prioritisation round of substances Info
- Deliverable 7.6 - 2nd prioritisation Report on survey design: Study protocols, SOPs and Guidelines, tailored and transferred questionnaires for recruitment and sampling Info
- Additional Deliverable 9.2 - Survey of tentative prices for biomarker analyses Info
- Deliverable 9.5 - Prioritised list of biomarkers, matrices and analytical methods for the 2nd prioritisation round of substances Info
- Deliverable 7.7 - 2nd set of materials for communication to participants, including informed consent Info
- Additional Deliverable 14.3 - WP14 - WP13 Interaction: Delineation of AOPs for the selection of effect biomarkers in the HBM4EU aligned studies Bisphenol A as a case-study Info
- Deliverable 5.4 A (phased) plan for action: from Human Biomonitoring to targeted policy action - Report of Case Study 1 – phthalates and bisphenols Info
- Deliverable 8.5 Initial Report on Occupational Studies Info
- Deliverable 4.6 Scoping documents for the second round priority substances Info
- Additional Deliverable 15.1 Plan for development of case studies Info
- Deliverable 13.3 - Inventory of available samples and data collected from existing cohorts and preliminary results on exposure- response associations for 1st list of priority substances Info
- HBM4EU MB meeting minutes - November 2018 Info
- HBM4EU MB meeting minutes - November 2018 Info
- HBM4EU MB meeting minutes - September 2018 Info
- HBM4EU MB meeting minutes - August 2018 Info
- HBM4EU MB meeting minutes - June 2018 Info
- HBM4EU MB meeting minutes - May 2018 Info
- HBM4EU MB meeting minutes - March 2018 Info
- HBM4EU MB meeting minutes - January 2018 Info
- HBM4EU MB meeting minutes - November 2017 Info
- HBM4EU MB meeting minutes - September 2017 Info
- HBM4EU MB meeting minutes - August 2017 Info
- HBM4EU MB meeting minutes - July 2017 Info
- HBM4EU MB meeting minutes - June 2017 Info
- HBM4EU MB meeting minutes - May 2017 Info
- HBM4EU MB meeting minutes - March 2017 Info
- HBM4EU MB meeting minutes - January 2017 Info
- PFAS Workshop 2018 Vienna - Presentations Info
- Deliverable 11.2 - Report on workshop about opportunities and obstacles for linking HBM and health studies Info
- Additional Deliverable 16.2 - Emerging chemicals framework Info
- Additional deliverable 12.4 - Conceptual design of the integrated computational platform Info
- Additional Deliverable 16.4 Emerging Substances Info